CytRx Corporation (NASDAQ: CYTR) CYTR previously reported that favorable data from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma was presented at the Sarcoma Poster-Discussion Session (Hall H) at the ESMO (European Society of Medical Oncology) 2012 Congress in Vienna, Austria. The presentation, entitled INNO-206 (aldoxorubicin) Is An Active Drug For Relapsed Soft Tissue Sarcoma, was given by renowned sarcoma expert Sant P. Chawla, M.D., Director of the Sarcoma Oncology Center in Santa Monica, CA. The data from the aldoxorubicin Phase 1b/2 clinical trial showed clinical benefit (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) with aldoxorubicin at the maximum tolerated dose in 10 of 13 (77%) evaluable patients with relapsed or refractory soft tissue sarcoma. CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, recently initiated both a Phase 2 trial for patients with advanced pancreatic ductal adenocarcinomas and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and plans to meet with the FDA in the fourth quarter of 2012 to discuss a potential Phase 3 pivotal trial as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and is in a Phase 2 clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about the Company,
visit www.cytrx.com. Jacobs Engineering Group Inc. (NYSE: JEC) JEC reported that it received a contract from the Washington State Department of Transportation (WSDOT) to provide on-call engineering and operations services in support of the agency's capital rail improvement program and other rail projects. The contract duration is three years and has a maximum value of 7 million, with an option to extend the duration and increase the value of the contract. Jacobs Engineering Group Inc. (NYSE: JEC) is one of the world's largest and most diverse providers of technical, professional, and construction services. For more information about Jacobs Engineering Group Inc. please visit www.jacobs.com. Crown Equity Holdings Inc. (CRWE) CRWE AD-Services, a division of CRWE is a full service multimedia advertising company specializing in internet marketing. Their goal is to provide you with a customized advertising blue print using their expansive resources. CRWE Ad Services (www.crwe-adservices.com ) provides modern and unique advertising campaigns. They are dedicated to offering the most cost effective advertising solutions. Furthermore, CRWE Tube (www.crwetube.com ), a video sharing site of CRWE, allows billions of people around the world to upload, watch and share original videos. With online videos continuing to experience explosive, viral growth and the web rapidly moving from text to video, businesses will need to adapt to the shift in video distribution technology or quickly become irrelevant to their consumers who anticipate seeing video everywhere online. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Crown Equity Holdings advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. For more information about Crown Equity Holdings Inc. visit www.crownequityholdings.com. THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: CRWEWallStreet.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://crwewallstreet.com/disclaimer).